Alterations of β-catenin and Tcf-4 instead of GSK-3β contribute to activation of Wnt pathway in hepatocellular carcinoma

Chinese Medical Journal

Volumn 116, Issue 12, 2003, Pages 1885-1892

  Cui, Jian ^a,c   Zhou, Xinda ^a   Liu, Yinkun ^a   Tang, Zhaoyou ^a   Mahmoud, Romeih ^b  

^a FUDAN UNIVERSITY   (China)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Etiology; Liver; Neoplasm; Signal transduction

Indexed keywords

AMINO ACID; BETA CATENIN; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; MYC PROTEIN; T CELL FACTOR PROTEIN; WNT PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; EXON; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; ONCOGENE C MYC; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM;

BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CYTOSKELETAL PROTEINS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TCF TRANSCRIPTION FACTORS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; WNT PROTEINS; ZEBRAFISH PROTEINS;

EID: 0742324050     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349:1269-1276.
2. Nagai H, Buendia MA. Oncogenes, tumor suppressors, and co-factors in hepatocellular carcinoma. In: Koshy R, Caselman W. eds. Hepatitis B virus. London: Imperial College Press; 1998:82-218.
3. de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998;95:8847-8851.
4. Miyoshi Y, Iwao K, Nagasawa Y, et al. Activation of the β-catenin gene in primary hepatocellular carcinoma by somatic alterations involving exon 3. Cancer Res 1998; 58: 2524-2527.
5. Nhieu J TV, Renard CA, Wei Y, et al. Nuclear accumulation of mutated β-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 1999;155:703-710.
6. Terris B, Pineau P, Bregeaud L, et al. Close correlation between β-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene 1999;18:6583-6588.
7. Legoix P, Bluteau O, Bayer J, et al. β-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 1999;18:4044-4046.
8. Kondo Y, Kanai Y, Sakamoto M, et al. β-catenin accumulation and mutation of exon 3 of the β-catenin gene in hepatocellular carcinoma. Jpn J Cancer Res 2000;90:1301-1309.
9. Hsu HC, Jeng YM, Mao TL, et al. β-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000;157:763-770.
10. Mao TL, Chu JS, Jeng YM, et al. Expression of mutant nuclear β-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol 2001;193:95-101.
11. Huang H, Fujii H, Sankila A, et al. β-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 1999;155:1795-1801.
12. Wong CM, Fan ST, Ng IOL. β-catenin mutation and over expression in hepatocellular carcinoma. Cancer 2001;92:136-145.
13. Cui J, Zhou XD, Liu YK, et al. Abnormal β-catenin gene expression with invasiveness of primary hepatocellular carcinoma in China. World J Gastroenterol 2001;7:542-546.
14. Cui J, Zhou XD, Liu YK, et al. Mutation and over expression of β-catenin gene may play an important role in primary hepatocellular carcinoma among Chinese people. J Cancer Res Clin Oncol 2001;127:577-581.
15. Pennisi E. How a growth control path takes a wrong turn to cancer. Science 1998;281:1438-1441.
16. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta 1997;1332:F127-F147.
17. Clevers H, van de Wetering M. TCF/LEF factors earn their wings. Trends Genet 1997;13:485-489.
18. He TC, Sparks AB, Rago C, et al. Identification of c-myc as a target of the APC pathway. Science 1998;281:1509-1512.
19. Tetsu O, McCormick F. β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-426.
20. Piao Z, Kim H, Jeon BK, et al. Regulation between loss of heterozygoisty of tumor suppressor gene and histological differentiation in hepatocellular carcinoma. Cancer 1997;80: 865-872.
21. Van Aken E, De Wever O, Lorreia Correia da Rocha AS, et al. Defective E-cadherin/catenin complexes in human cancers. Virchows Arch 2001;439:725-751.
22. Yu SZ. Primary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol 1995;10:674-682.
23. Tang ZY. Hepatocellular carcinoma: cause, treatment and metastasis. World J Gastroenterol 2001;7:445-454.
24. Kitagawa M, Hatakeyama S, Shirane M, et al. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of β-catenin. EMBO J 1999;18:2401-2410.
25. Udatsu Y, Kusafuka T, Kuroda S, et al. High frequency of β-catenin mutations in hepatoblastoma. Pediatr Surg Int 2001;17:508-512.
26. Rubinfeld B, Souza B, Albert I, et al. Association of the APC gene product with P-catenin. Science 1993;262:1737-1744.
27. Su LK, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein with catenins. Science 1993;262: 1734-1737.
28. Satoh S, Daigo Y, Furukawa Y, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000; 24:245-250.
29. Inagawa S, Itabashi M, Adachi S, et al. Expression and prognostic roles of β-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res 2002;8:450-456.
30. Sparks AB, Morin PJ, Vogestein B, et al. Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998;58:1130-1134.
31. Korinek V, Barker N, Moerer P, et al. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Gen 1998;19:379-383.
32. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997;275:1784-1787.
33. Duval A, Gayet J, Zhou XP, et al. Frequent frameshift mutations of the TCF-4 gene in colorectal cancers with microsatellite instability. Cancer Res 1999;59:4213-4215.
34. Duval A, Rolland S, Tubacher E, et al. The human T-cell transcription factor-4 gene: structure, extensive characterization of alternative splicings, and mutational analysis in colorectal cancer cell lines. Cancer Res 2000;60:3872-3879.
35. Di Bisceglie AM. Hepatocellular carcinoma: molecular biology of its growth and relationship to hepatitis B virus infection. Med Clin North Am 1989;73:985-997.
36. Monga SP, Pediaditakis P, Mule K, et al. Changes in WNT/ β-catenin pathway during regulated growth in rat liver regeneration. Hepatology 2001;33:1098-1109.
37. Gottardi CJ, Wong E, Gumbiner BM. E-cadherin suppresses cellular transformation by inhibiting β-catenin signaling in an adhesion-independent manner. J Cell Biol 2001;153:1049-1060.
38. Huber O, Bierkamp C, Kemle R. Cadherins and catenins in development. Curr Opin Cell Biol 1996;8:685-691.